Background: Relapse of the nephrotic syndrome is co mmon among patients with primary membranous nephropathy (MN). Relapses of MN typically occur within a few years of achieving disease remission. There is limited description, to date, regarding patients with MN who have late relapse of MN, i.e., after >5 years of sustained disease remission. The objective of this case series was to report the clinical course of patients with MN who experience late relapse. Methods: We analyzed the patient database of the Glomerular Kidney Disease Center at Columbia University to identify patients seen at our center who had relapse of biopsy specimen-proven MN at least 5 years after achieving sustained disease remission. Results: We identified 16 patients with late relapse of MN. The median time in sustained remission before relapse was 10.2 (range, 7-29.0) years. Ten patients (63%) were diagnosed with late relapse on the basis of laboratory monitoring alone, without clinical symptoms of the nephrotic syndrome. Fourteen patients (88%) received immunosuppression during their initial presentation and late relapse. Patients had favorable long-term renal outcomes over a median 21 (range, 12-56) year follow-up period, with 14 patients (88%) in remission at study conclusion and a median decline in eGFR per year of -0.63 (range, -6.3 to 17.5) ml/min per 1.73 m2 per year. Conclusions: This case series highlights a previously underappreciated, and likely rare, outcome of MN, namely, late relapse. Patients who experience late relapse, and who thus have a longer time in sustained remission, may have a more favorable long-term renal outcome.
Background: Relapse of the nephrotic syndrome is co mmon among patients with primary membranous nephropathy (MN). Relapses of MN typically occur within a few years of achieving disease remission. There is limited description, to date, regarding patients with MN who have late relapse of MN, i.e., after >5 years of sustained disease remission. The objective of this case series was to report the clinical course of patients with MN who experience late relapse. Methods: We analyzed the patient database of the Glomerular Kidney Disease Center at Columbia University to identify patients seen at our center who had relapse of biopsy specimen-proven MN at least 5 years after achieving sustained disease remission. Results: We identified 16 patients with late relapse of MN. The median time in sustained remission before relapse was 10.2 (range, 7-29.0) years. Ten patients (63%) were diagnosed with late relapse on the basis of laboratory monitoring alone, without clinical symptoms of the nephrotic syndrome. Fourteen patients (88%) received immunosuppression during their initial presentation and late relapse. Patients had favorable long-term renal outcomes over a median 21 (range, 12-56) year follow-up period, with 14 patients (88%) in remission at study conclusion and a median decline in eGFR per year of -0.63 (range, -6.3 to 17.5) ml/min per 1.73 m2 per year. Conclusions: This case series highlights a previously underappreciated, and likely rare, outcome of MN, namely, late relapse. Patients who experience late relapse, and who thus have a longer time in sustained remission, may have a more favorable long-term renal outcome.
Authors: Fernando C Fervenza; Gerald B Appel; Sean J Barbour; Brad H Rovin; Richard A Lafayette; Nabeel Aslam; Jonathan A Jefferson; Patrick E Gipson; Dana V Rizk; John R Sedor; James F Simon; Ellen T McCarthy; Paul Brenchley; Sanjeev Sethi; Carmen Avila-Casado; Heather Beanlands; John C Lieske; David Philibert; Tingting Li; Lesley F Thomas; Dolly F Green; Luis A Juncos; Lada Beara-Lasic; Samuel S Blumenthal; Amy N Sussman; Stephen B Erickson; Michelle Hladunewich; Pietro A Canetta; Lee A Hebert; Nelson Leung; Jay Radhakrishnan; Heather N Reich; Samir V Parikh; Debbie S Gipson; Dominic K Lee; Bruno R da Costa; Peter Jüni; Daniel C Cattran Journal: N Engl J Med Date: 2019-07-04 Impact factor: 91.245
Authors: Peter D Burbelo; Megha Joshi; Adrija Chaturvedi; Dustin J Little; John S Thurlow; Meryl Waldman; Stephen W Olson Journal: J Am Soc Nephrol Date: 2019-12-16 Impact factor: 10.121
Authors: Michelle A Hladunewich; Stephan Troyanov; Jennifer Calafati; Daniel C Cattran Journal: Clin J Am Soc Nephrol Date: 2009-08-06 Impact factor: 8.237
Authors: Horia C Stanescu; Mauricio Arcos-Burgos; Alan Medlar; Detlef Bockenhauer; Anna Kottgen; Liviu Dragomirescu; Catalin Voinescu; Naina Patel; Kerra Pearce; Mike Hubank; Henry A F Stephens; Valerie Laundy; Sandosh Padmanabhan; Anna Zawadzka; Julia M Hofstra; Marieke J H Coenen; Martin den Heijer; Lambertus A L M Kiemeney; Delphine Bacq-Daian; Benedicte Stengel; Stephen H Powis; Paul Brenchley; John Feehally; Andrew J Rees; Hanna Debiec; Jack F M Wetzels; Pierre Ronco; Peter W Mathieson; Robert Kleta Journal: N Engl J Med Date: 2011-02-17 Impact factor: 91.245
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Aikaterini Nikolopoulou; Isabel Huang-Doran; Stephen P McAdoo; Megan E Griffith; H Terence Cook; Charles D Pusey Journal: Kidney Int Rep Date: 2019-08-13